AI-based antibody discovery platform identifies novel, diverse, and pharmacologically active therapeutic antibodies against multiple SARS-CoV-2 strains
These first-generation antibodies, without the need for affinity maturation, exhibited neutralization of SARS-CoV-2 viral infectivity across multiple strains and indicated high developability potential.
Authors
- Megan Sprague
- Danielle Van Citters (ORCID: https://orcid.org/0000-0001-6599-5190)
- Laurence Somody
- Derrick Deming
- Christine C. Siska
- Tileli Amimeur
- Grégory Neveu (ORCID: https://orcid.org/0000-0002-2363-6031)
- Randal R. Ketchem (ORCID: https://orcid.org/0000-0002-7821-2682)
- Cristina Moldovan Loomis
- Jeremy M. Shaver (ORCID: https://orcid.org/0000-0002-4853-5130)
- Thomas Lahlali (ORCID: https://orcid.org/0000-0002-9260-9811)
- Antoine Alam (ORCID: https://orcid.org/0000-0002-4379-9321)
- Caroline Carbonelle
- Andrew Asakawa
- Rutilio H. Clark
Institutions
- Evotec (United States) (US)
Publication Details
- Journal
- Antibody Therapeutics
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1093/abt/tbae025
- Citations
- 7
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.72